phenoxodiol

Phase 3Small molecule

MMEI Pharma, Inc.

phenoxodiol is one of 55 small molecule programs targeting Prostate Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Ovarian CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

phenoxodiol

MMEI Pharma, Inc.

Phase 3

1 2

Novantrone

Pfizer

Preclinical

5 3

Trexall

Alnylam Pharmaceuticals

Preclinical

—4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 5

Duragesic

CCephalon

Preclinical

1 6

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 7

Prednisone/prednisolone

Roche

Preclinical

3 8

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

—9

Ifex

BBaxter Healthcare Corporation

Preclinical

—10

Therapeutic Hydrocortisone

EEastern Cooperative Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ovarian Cancer1 trial

OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer

Completed·MMEI Pharma, Inc.·Phase 3·NCT00382811·142 enrolled

Prostate Cancer1 trial

A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Prostate Cancer

Completed·MMEI Pharma, Inc.·Phase 2·NCT00557037·60 enrolled

Primary Peritoneal Cancer1 trial

Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Completed·MMEI Pharma, Inc.·Phase 1/2·NCT00091377·65 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for phenoxodiol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — phenoxodiol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for phenoxodiol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — MEI Pharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMEI Pharma, Inc.

phenoxodiol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ovarian Cancer1 trial

Prostate Cancer1 trial

Primary Peritoneal Cancer1 trial

References

Drug Info

Quick Facts

Related News